OBJECTIVES: The study assessed the incremental economic and humanistic burden of psoriatic arthritis (PsA) from a large multinational survey of dermatologists and their psoriasis patients. METHODS: This cross-sectional observational study was conducted in EU5, Russia, Mexico, Brazil and South Korea between September 2015 and January 2016. Eligible patients currently have or have ever had moderate to severe psoriasis, and are current users of prescribed systemic agents or topical treatments at time of the survey. Generalized linear models with appropriate distributions and link functions were developed to compare medical resource utilization in the past 12 months, health-related quality of life (HRQoL: Dermatology Life Quality Index [DLQI] and EQ-5D) and overall work impairment from the Work Productivity and Activity Impairment questionnaire between patients with and without PsA, adjusted for demographic, disease severity and treatment effects. RESULTS: Amongst 3821 patients, 624 (16%) were diagnosed with PsA. Compared to patients without PsA, patients with PsA had longer duration since diagnosis of psoriasis (12.8 vs. 8.5 years, p<0.0001), greater severity of psoriasis (PASI score of 7.8 vs. 6.2, p<0.0001), more exacerbations in the past 12 months (p<0.0001) and were more likely to have painful skin (odds ratio [OR]=1.4, 95% confidence interval [CI]=[1.1; 1.8]) and joint pain (OR = 47.6, 95% CI=[33.3, 69.2]). Patients with PsA were more likely to have psoriasis-related outpatient visits (OR=1.4, 95% CI=[1.1; 1.8]), dermatologist visits (18.1% increase, p<0.0001) and rheumatologist involvement (OR=26.5, 95% CI=[18.6; 38.6]). They had worse HRQoL (1.6 and 0.1 increase of mean DLQI score and mean EQ-5D utility weight respectively, p<0.0001), and greater work impairment (27% increase of mean overall work impairment score, p=0.01). CONCLUSIONS: Results from this large real-life survey confirmed the economic and humanistic burden associated with PsA and highlight the need for effective therapies to control both psoriasis and PsA.